Regina Heidenreich
Overview
Explore the profile of Regina Heidenreich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rauch S, Lutz J, Muhe J, Kowalczyk A, Schlake T, Heidenreich R
Methods Mol Biol
. 2024 May;
2786:183-203.
PMID: 38814395
Developing effective mRNA vaccines poses certain challenges concerning mRNA stability and ability to induce sufficient immune stimulation and requires a specific panel of techniques for production and testing. Here, we...
2.
Lutz J, Meister M, Habbeddine M, Fiedler K, Kowalczyk A, Heidenreich R
Cancer Immunol Immunother
. 2022 Nov;
72(5):1075-1087.
PMID: 36319717
Immunotherapy has revolutionized cancer treatment in recent years. Although currently approved checkpoint inhibitors (CPIs) yield remarkable anti-tumoral responses in several cancer types, a substantial proportion of patients do not benefit...
3.
Loffler M, Gori S, Izzo F, Mayer-Mokler A, Ascierto P, Konigsrainer A, et al.
Clin Cancer Res
. 2022 Apr;
28(12):2555-2566.
PMID: 35421231
Purpose: Immunotherapy for hepatocellular carcinoma (HCC) shows considerable promise in improving clinical outcomes. HepaVac-101 represents a single-arm, first-in-human phase I/II multicenter cancer vaccine trial for HCC (NCT03203005). It combines multipeptide...
4.
Schlake T, Thran M, Fiedler K, Heidenreich R, Petsch B, Fotin-Mleczek M
Mol Ther
. 2019 Mar;
27(4):773-784.
PMID: 30885573
First attempts to use exogenous mRNA for protein expression in vivo were made more than 25 years ago. However, widespread appreciation of in vitro transcribed mRNA as a powerful technology...
5.
Doener F, Hong H, Meyer I, Tadjalli-Mehr K, Daehling A, Heidenreich R, et al.
Vaccine
. 2019 Feb;
37(13):1819-1826.
PMID: 30797640
Background: We report the first-in-concept human trial of the safety, tolerability and immunogenicity when a novel TLR 7/8/RIG I agonist RNA-based adjuvant, CV8102, was administered alone or mixed with fractional...
6.
Basler L, Kowalczyk A, Heidenreich R, Fotin-Mleczek M, Tsitsekidis S, Zips D, et al.
Cancer Immunol Immunother
. 2018 Jan;
67(4):653-662.
PMID: 29335856
Background: Tumor metastasis and immune evasion present major challenges of cancer treatment. Radiotherapy can overcome immunosuppressive tumor microenvironments. Anecdotal reports suggest abscopal anti-tumor immune responses. This study assesses abscopal effects...
7.
Lutz J, Lazzaro S, Habbeddine M, Schmidt K, Baumhof P, Mui B, et al.
NPJ Vaccines
. 2017 Dec;
2:29.
PMID: 29263884
mRNA represents a promising new vaccine technology platform with high flexibility in regard to development and production. Here, we demonstrate that vaccines based on sequence optimized, chemically unmodified mRNA formulated...
8.
Thran M, Mukherjee J, Ponisch M, Fiedler K, Thess A, Mui B, et al.
EMBO Mol Med
. 2017 Aug;
9(10):1434-1447.
PMID: 28794134
The delivery of genetic information has emerged as a valid therapeutic approach. Various reports have demonstrated that mRNA, besides its remarkable potential as vaccine, can also promote expression without inducing...
9.
Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R
Recent Results Cancer Res
. 2017 Jan;
209:61-85.
PMID: 28101688
mRNA cancer vaccines are a relatively new class of vaccines, which combine the potential of mRNA to encode for almost any protein with an excellent safety profile and a flexible...
10.
Ziegler A, Soldner C, Lienenklaus S, Spanier J, Trittel S, Riese P, et al.
J Immunol
. 2017 Jan;
198(4):1595-1605.
PMID: 28077601
Among innovative adjuvants conferring a Th1-shift, RNAdjuvant is a promising candidate. This adjuvant consists of a 547-nt uncapped noncoding ssRNA containing polyU repeats that is stabilized by a cationic carrier...